三重阴性乳腺癌:在二十年内从没有到多个治疗点
1Department of Pathology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Frontiers in oncology
|November 29, 2023
概括
三阴性乳腺癌 (TNBC) 是一种异质的癌症,预后不佳. 了解TNBC分子亚型的进步导致了新的免疫疗法和向药物,如PARP抑制剂和抗体药物联合体 (ADC).
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 三阴性乳腺癌 (TNBC) 由于其侵袭性质和缺乏向治疗方法,构成了重大临床挑战.
- TNBC的特点是分子异质性,需要对其亚型有更深入的了解,才能有效治疗.
- 缺少雌激素受体,孕激素受体和HER2过度表达定义了TNBC,限制了传统的治疗选择.
研究的目的:
- 提供三阴性乳腺癌分子基础的系统审查.
- 探索TNBC新兴的治疗策略和生物标志物.
- 要突出转向免疫治疗和针对性药物开发的范式转变在TNBC.
主要方法:
- 在过去二十年中对TNBC研究进行系统的文献审查.
- 分子亚型及其临床影响的分析.
- 评估当前和新型治疗方法,包括免疫疗法,PARP抑制剂和抗体药物联合体 (ADCs).
主要成果:
- TNBC 含有更高频率的生殖系 BRCA 突变,通过合成致死性为 PARP 抑制剂提供了目标.
- 识别新的分子标为ADC等先进疗法铺平了道路.
- 免疫疗法已经成为一个有前途的策略,从根本上改变了TNBC的治疗格局.
结论:
- 对TNBC分子复杂性的全面了解对于开发个性化治疗策略至关重要.
- 包括PARP抑制剂和ADC在内的向疗法,以及免疫疗法,代表了TNBC管理的重大进展.
- 对生物标志物的持续研究对于优化TNBC患者选择和治疗疗效至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


